← Leaderboards
Brianna Mullins
Salus Discovery, Llc
$1,866,165
Attributed
$3,877,786
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,877,786 · 6
By mechanism
R44$2,751,524 · 2
R43$1,126,262 · 4
Top collaborators
- Scott M Berry4 shared
- Jay Wyatt Warrick4 shared
- Cody Carrell1 shared
Most similar at Salus Discovery, Llc
Same institution · by research overlap
- Jay Wyatt Warrick$3,077,992
- Cody Carrell$745,861
Others in their field
Other Emerging Leaders on “Detection”
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Mark Marino · Venturewell$48,913,644
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Stuart Hellyar Hellyar$34,175,230
- Bryan Faller · Decatur Memorial Hospital$29,346,991
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
Research focus
DetectionTechnologyPerformancePoint Of CareDiagnosticSamplingDevicesLaboratoriesPreparationCessation Of LifeSample CollectionBenchmarkingPathogenInterestCostDiagnostic SensitivityClinical SensitivityFirst-In-HumanDesignAdultCommercializationNew TechnologyDiagnosisHuman Study
Grant awards (8)
Enhancing Pediatric Diagnosis of Tuberculosis with FLOW Technology$818,507
R44 · FY2024 · HD · contact PI
3STEP: A swab-seal-read, point-of-care nucleic acid test to address disparity in STI screening and prevention$275,736
R43 · FY2024 · AI · contact PI
Enhancing detection and mobile monitoring of schistosomiasis with urine-based analyte pre-concentration technology$275,526
R43 · FY2023 · AI · contact PI
Enhancing Pediatric Diagnosis of Tuberculosis with FLOW Technology$962,850
R44 · FY2022 · HD · contact PI
Enhancing Pediatric Diagnosis of Tuberculosis with FLOW Technology$436,366
R44 · FY2020 · HD · contact PI
Getting More from Less: Multi-omic Capture and Analysis from Patient Samples$533,801
R44 · FY2018 · GM · contact PI
Seeing the unseen: Enhancing purification of labile protein complexes and cells with low surface marker expression$350,000
R43 · FY2018 · OD · contact PI
Development of a cell based assay to assess antigen specific tolerance$225,000
R43 · FY2018 · AI · contact PI